Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy with the storage mite lepidoglyphus destructor

A Armentia-Medina1, J A Tapias, J F Martín

  • 1Division of Allergy and Pneumology, Rio Hortega Hospital, University of Valladolid, Spain.

Allergologia Et Immunopathologia
|September 1, 1995
PubMed
Summary

Specific immunotherapy for Lepidoglyphus destructor (Ld) allergy improved patient symptoms and reduced reactivity. The treatment showed significant clinical benefits without severe side effects, indicating its safety and efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-ACTH antibodies in critically ill Covid-19 patients: A potential immune evasion mechanism of SARS-CoV-2.

Medicina intensiva·2022
Same author

Anti-ACTH antibodies in critically ill Covid-19 patients: A potential immune evasion mechanism of SARS-CoV-2.

Medicina intensiva·2021
Same author

Genetic localisation of mental retardation with spastic diplegia to the pericentromeric region of the X chromosome: X inactivation in female carriers.

Journal of medical genetics·1998
Same author

Acute disseminated candidiasis in a puppy associated with parvoviral infection.

The Veterinary record·1998
Same author

[Surgical treatment of lung abscesses].

Revista do Hospital das Clinicas·1998
Same author

[Risperidone in the treatment of acute exacerbation of schizophrenia symptoms].

Actas luso-espanolas de neurologia, psiquiatria y ciencias afines·1998

Area of Science:

  • Allergy and Immunology
  • Clinical Trials
  • Respiratory Medicine

Background:

  • Storage mite allergy, particularly to Lepidoglyphus destructor (Ld), is a significant cause of allergic respiratory diseases.
  • Current treatment options include avoidance and symptomatic therapy, but specific immunotherapy offers a potential disease-modifying approach.

Purpose of the Study:

  • To evaluate the efficacy and safety of specific immunotherapy in patients sensitized to Lepidoglyphus destructor.
  • To assess changes in clinical symptoms, immunological parameters, and airway hyperresponsiveness following immunotherapy.

Main Methods:

  • A double-blind, placebo-controlled clinical trial was conducted on 35 patients with Lepidoglyphus destructor sensitization.
  • In vivo (skin tests, methacholine challenge) and in vitro (specific IgE, IgG, IgG1, IgG4) assays were performed before and after 12 months of immunotherapy.

Related Experiment Videos

  • Clinical efficacy was monitored through symptom scores, medication use, and patient self-evaluation.

    • Main Results:

    • Immunotherapy significantly reduced skin reactivity, positive challenge test doses, and methacholine hyperresponsiveness.
    • Sputum eosinophilia decreased, while specific IgE to Ld increased, accompanied by elevated specific IgG1 and IgG4 to Ld and its major allergen Lep dI.
    • No severe adverse reactions or circulating immune complexes were observed; placebo group showed no significant changes.

    Conclusions:

    • Specific immunotherapy for Lepidoglyphus destructor allergy is effective in reducing allergic reactivity and improving clinical outcomes.
    • The treatment is safe, well-tolerated, and associated with favorable patient self-assessment and reduced work absence.
    • Observed immunological shifts, including increased specific IgG subclasses, may contribute to the therapeutic benefits.